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Human adenovirus type 4 (Ad4), the sole member of subgroup E, contains an open reading frame in the E3 region predicted
to encode a unique 30-kDa protein (named Ad4E3-30K). Ad4E3-30K is predicted to be an integral membrane protein
containing an N-terminal signal sequence, a lumenal domain, a transmembrane domain near the C-terminus, and a
37-amino-acid cytoplasmic tail. To determine whether this protein is expressed, rabbit polyclonal antisera were raised
against 30K-containing fusion proteins expressed in bacteria. A 30K protein was detected by immunoprecipitation from
cell-free translation products and from Ad4-infected A549 cells radiolabeled in the presence of tunicamycin. The protein was
detected at only low levels in infected cells. It was not synthesized by a mutant with a large E3 deletion that includes the
Ad4E3-30K gene. This mutant grows as well as wild-type Ad4 in culture. Features of Ad4E3-30K were characterized in
different transient expression systems. The protein underwent glycosylation by addition of approximately six asparagine-
linked oligosaccharides. These glycans were sensitive to endoglycosidase H, indicating that they were either high-mannose
or hybrid types, but not complex types, and that the protein did not pass through the Golgi apparatus. Immunofluorescence
staining of transfected cells revealed that Ad4E3-30K was localized primarily in the endoplasmic reticulum and nuclear











The E3 region of human adenoviruses (Ads) encodes
several proteins that are conserved among all six sub-
groups (A–F) (Fig. 1). In subgroup C, these conserved E3
proteins are named E3-12.5K (MW of 12,500), gp19K
(which is not found in subgroup A), RIDa (receptor inter-
nalization and degradation a, previously named
E3-10.4K), RIDb (E3-14.5K), and E3-14.7K (reviewed in
Wold et al., 1995c). There are two additional subgroup C
E3 proteins, E3-6.7K and adenovirus death protein (ADP,
previously named E3-11.6K), that are not well conserved
among the subgroups (Fig. 1). The E3 proteins are ini-
tially expressed during “early” stages of infection, before
the onset of viral DNA synthesis (Shenk, 1996), and are
not required for viral replication in cell culture (Wold and
Gooding, 1991).
Previous studies demonstrated that the general func-
tion of some of the E3 proteins of Ad2 and Ad5 (sero-
types in subgroup C) is to counteract host defenses that
would ordinarily eliminate virus-infected cells (Wold and
Gooding, 1991; Wold et al., 1995a, 1995b, 1995c, 1999a,
1999b; Wold and Tollefson, 1998, 1999; Mahr and Good-
ing, 1999). For example, E3-gp19K prevents cytotoxic
T-lymphocytes from lysing cells by blocking transport of
1 To whom correspondence and reprint requests should be ad-
ressed. Fax: (314) 773-3403. E-mail: woldws@slu.edu.
127nascent MHC class I molecules from the endoplasmic
reticulum (ER) to the cell surface (Kvist et al., 1978; Paabo
et al., 1983; Anderson et al., 1985, 1987; Burgert and Kvist,
1985; Burgert et al., 1987; Jackson et al., 1993). The
E3-14.7K protein prevents apoptosis induced by tumor
necrosis factor a (TNFa) (Gooding et al., 1988, 1990;
orton et al., 1990, 1991). The mechanism of E3-14.7K
ction is not clear, but it probably involves inhibition of
NFa-induced proteolysis (Voelkel-Johnson et al., 1995),
nhibition of TNFa-induced arachidonic acid release (Zilli
t al., 1992; Krajcsi et al., 1996), and interaction with
ellular proteins, e.g., FIP-1 (14.7K interacting protein) (Li
t al., 1997), FIP-2 (Li et al., 1998), and FIP-3 (Li et al.,
999). The E3 protein named RID (a complex of RIDa and
RIDb) prevents cytolysis by TNFa (Gooding et al., 1991)
y a mechanism that is independent of the 14.7K protein
Krajcsi et al., 1996). RID also inhibits Fas-agonist in-
duced apoptosis by down-regulating Fas (Shisher et al.,
1997; Tollefson et al., 1998; Elsing and Burgert, 1998); in
this process, RID forces Fas to be internalized from the
cell surface and then be degraded in liposomes (Tollef-
son et al., 1998). RID also down-regulates the cell sur-
face epidermal growth factor receptor (Carlin et al., 1989;
Tollefson et al., 1991; Stewart et al., 1995). E3-ADP, a
membrane protein that is expressed early but is synthe-
sized in much greater abundance at late stages of infec-
tion (Scaria et al., 1992; Tollefson et al., 1992), is involved
in lysis of infected cells and release of virus from cells
0042-6822/00 $35.00
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128 LI AND WOLD(Tollefson et al., 1996a,b). The E3-6.7K protein is an
Asn-linked type III integral membrane glycoprotein that
is retained in the ER (Wilson-Rawls et al., 1990, 1993,
1994). The E3-12.5K protein does not appear to be a
membrane protein (Hawkins and Wold, 1992). The func-
tions of E3-6.7K and E3-12.5K are not known.
The E3 regions of subgroups A, B, D, and E are
predicted by their DNA sequence to encode additional
membrane proteins not found in subgroup C (Wold et al.,
1995c). Serotypes in the different subgroups differ in their
tissue tropisms and pathogenic properties (Horwitz,
1996), and it is conceivable that some of these differ-
ences are due to the different E3 proteins. Within sub-
group B, the E3-20.5K protein is synthesized as a mem-
brane protein with O-linked and complex N-linked gly-
cans (Hawkins and Wold, 1995a,b). The E3-16K
membrane protein is also expressed; surprisingly, it is
not glycosylated (Hawkins et al., 1995). The functions of
the E3-20.5K and E3-16K proteins are not known.
Human Ad4 is the only member of subgroup E. Ad4 is
an important pathogen (Horwitz, 1996), causing acute
respiratory disease in military recruits (Sonoguchi and
Fukumi, 1967; Rosenvaum et al., 1968; Dudding et al.,
1972; Top, 1975; Barraza et al., 1999), acute hemorrhagic
conjunctivitis (Muzzi et al., 1975; Tullo and Higgins, 1980;
Levandowski and Rubenis, 1981; Babaloa et al., 1990;
Schepetiuk et al., 1993; Tsuki-Wang et al., 1997), and fatal
nonbacterial pneumonia (Levin et al., 1967). It was used
to vaccinate military recruits against acute respiratory
disease (Top et al., 1971). A recent outbreak reported in
FIG. 1. Predicted E3 proteins of adenoviruses in different human sub
oxes. The RIDa, RIDb, and 14.7K proteins are conserved among all s
ADP protein of subgroup C (Ad2 and Ad5) is conserved (distantly) in s
(Ad4E3-30K) of subgroup E and the Ad9 31K protein of subgroup D. T
localization in the cytoplasm; N, localization in nucleus; ER M, localiza
membrane; PM, localization in the plasma membrane; gp, glycoproteinunvaccinated soldiers during a lapse in vaccination dem-
onstrates continued susceptibility of military recruits to
t
tAd4 and warns of future outbreaks (Barraza et al., 1999).
Ad4 is also a candidate vaccine vector for expression of
heterologous viral proteins (Chengalvala et al., 1991a,
1991b, 1994, 1997; Hsu et al., 1992, 1994; Natuk et al.,
992, 1994, 1995; Lubeck et al., 1995). Some biological
nd biochemical properties of Ad4 resemble those of the
espiratory serotypes from subgroups B and C (Gruber et
l., 1993).
The E3 region of Ad4 contains eight or nine open
eading frames (ORFs), five of which are similar to those
ound in Ad2 and Ad5 (Fig. 1). Ad4 E3 also has two ORFs
hat are predicted to encode novel membrane proteins
ith molecular weights of 30K and 27K located between
he genes for gp19K and RIDa (Fig. 1). The 30K protein,
hereafter named Ad4E3-30K, is predicted to be an Asn-
glycosylated membrane-associated protein containing
an N-terminal signal sequence and a C-terminal trans-
membrane domain (Fig. 2, top). Here we demonstrate
that Ad4E3-30K is expressed as a glycoprotein in Ad4-
infected cells and in transiently transfected cells.
RESULTS
Immunoprecipitation of the Ad4E3-30K protein
synthesized by cell-free translation
The predicted sequence of the Ad4E3-30K protein (274
amino acids) based on the ORF is shown in Fig. 2 (top).
Two Ad4E3-30K fusion proteins, GST–30K and His6–30K,
were expressed in Escherichia coli as proteins of ap-
roximately 65 and 33 kDa, respectively, consistent with
. Conserved proteins or subregions of proteins are shown by identical
ps, and gp19K is conserved in all subgroups except subgroup A. The
p B1, and there is very weak homology to ADP in the Ad4 30K protein
s in subgroups C, D, A, and F indicate the absence of the protein. C,
the endoplasmic reticulum membrane; NM, localization in the nucleargroups
ubgrou
ubgrou
he lineheir predicted molecular masses. Purified forms of













































129CHARACTERIZATION OF Ad4E3-30Ksulting polyclonal antiserum immunoprecipitated a pro-
tein with an apparent molecular mass of 30K from cell-
free transcription/translation reactions with plasmids en-
coding the putative 30K ORF under control of the T7
promoter (Fig. 3). The preimmune serum was nonreac-
tive.
Immunoprecipitation of the Ad4E3-30K protein from
Ad4-infected A549 cells
To demonstrate that the ORF for Ad4E3-30K is indeed
expressed in Ad4-infected cells, immunoprecipitation
was conducted on Ad4-infected A549 cells using the
rabbit antiserum. The Ad4E3-30K protein contains three
cysteines and only one methionine downstream of the
signal peptide sequence, so [35S]cysteine and [35S]me-
hionine were used for labeling. In these experiments, a
0K protein was not detected by either immunoprecipi-
ation or Western blot when A549 cells were infected
ith wild-type Ad4, although the other Ad4 E3 proteins
gp19K and 14.7K) were detected (data not shown). We
onsidered the possibility that glycosylation of Ad4E3-
0K could result in multiple diffuse bands, which could
ake detection of the protein difficult. Therefore, cells
ere treated with tunicamycin, which blocks N-glycosyl-
FIG. 2. Primary structure of the Ad4E3-30K protein and schematic of
its main structural features, consisting of NH2-terminal signal peptide
and COOH-terminal transmembrane regions (indicated by lined re-
gions above the sequence) and lumenal and short cytoplasmic regions.
Six potential N-linked glycosylation sites (NXS/T) are underlined (top).
The hydropathicity plot (Kyte–Doolittle) shows two regions of relatively
high hydrophobicity, corresponding to the signal sequence and trans-
membrane regions (bottom).tion, before and during labeling. A 30K protein was
btained by immunoprecipitation from cells infected with
c
bild-type Ad4, but not from cells infected with an E3-
eletion mutant (Fig. 4a, lanes c, d, g, and h). Accordingly,
unicamycin was used in subsequent experiments to
rovide reproducible detection of the Ad4E3-30K protein.
hese data suggest that the Ad4E3-30K protein is ex-
ressed from the E3 region during Ad4 replication in a
uman cell line.
he Ad4E3-30K protein is expressed at the early
tage of infection and is amplified at the late stage
An understanding of the role that Ad4E3-30K plays in
irus replication requires that we know when the protein
s synthesized at different stages of infection. The early–
ate transition in Ad2 and Ad5 occurs at approximately
h postinfection (p.i.). The timing of this transition with
d4 is not known, although it probably is similar. The E3
roteins are early proteins whose expression begins
efore viral DNA replication. However, they are also
xpressed at the late stage of infection, sometimes in
ncreased abundance, from mRNAs derived from the
ajor late transcription unit. This is the case with ADP in
he E3 region of Ad2 and Ad5 (Tollefson et al., 1992).
The Ad4E3-30K gene is located in the same genome
position in Ad4 E3 as the adp gene in the Ad2 and Ad5
E3 region, and its expression might be regulated like that
of ADP. In order to estimate when the Ad4E3-30K protein
is expressed, infected cells were labeled in the absence
and in the presence of 1-b-D-arabinofuranosylcytosine
Ara-C); Ara-C inhibits viral DNA replication and therefore
revents synthesis of viral late proteins (Fig. 4c, lanes b
nd c compared with lanes e and f). The immunoprecipi-
ation data from 4-h pulse-labeling experiments showed
hat Ad4E3-30K was expressed in the absence or in the
resence of Ara-C and that it was expressed in greater
bundance in the absence of Ara-C (Fig. 4a). This result
ndicates that expression of the protein began at the
arly stage of infection and was amplified at late stages.
A time-course analysis of Ad4E3-30K protein expres-
ion in Ad4-infected A549 cells showed that the protein
FIG. 3. Immunoprecipitation of the Ad4E3-30K protein synthesized by
cell-free translation. [35S]cysteine-labeled Ad4E3-30K protein synthe-
ized in reticulocyte lysates was immunoprecipitated with a rabbit
olyclonal antiserum and analyzed by SDS–PAGE followed by autora-
iography. (2) indicates lysate without immunoprecipitation. “Pre” indi-
ates preimmune serum. Numbers indicate consecutive bleeds after
oosting injections.
f most
130 LI AND WOLDwas detectable at 24 to 30 h p.i. and reached a peak level
at 27 to 30 h p.i. (Fig. 4b). These data again indicate that
the protein continues to be expressed at the late stage of
infection.
Detection of the Ad4E3-30K protein in transfected
cells
To characterize further the features of Ad4E3-30K dur-
ing expression in mammalian cells, transient expression
systems were established. The recombinant vaccinia
virus vTF7-3 expression system provides a wide host
range for protein expression after DNA transfection and
enables high-efficiency expression from plasmids en-
FIG. 4. Detection of the Ad4E3-30K protein in Ad4-infected cells. A54
and labeled for 4 h at different times p.i. with [35S]cysteine and [35S]meth
DNA replication and prevents synthesis of viral late proteins. Tunicamyc
of Ara-C. (b) A time course of Ad4E3-30K expression in Ad4-infected A54
mutant virus, respectively. The 48-h samples are blank due to death o
in the presence of Ara-C (without immunoprecipitation).coding recombinant proteins (Fuerst et al., 1986). In this
system, T7 RNA polymerase produced by recombinantvaccinia virus drives expression of proteins derived from
plasmids delivered to cells by DNA transfection. The
Ad4E3-30K ORF was inserted into three different plasmid
vectors containing the T7 promoter (pTM1, pcDNA3.1,
and pCRII). When expressed from the construct
pcDNA3.1(2)/30K-myc-His, either in the absence or in
the presence of tunicamycin, the Ad4E3-30K protein
could be detected either by immunoprecipitation of
[35S]methionine plus [35S]cysteine-labeled protein (Fig. 5,
lanes b and c) or by Western blot with rabbit anti-30K
antiserum (data not shown). All three 30K-expressing
plasmids expressed the Ad4E3-30K protein in this tran-
sient transfection in both SW-13 and COS cells, and all
were infected (m.o.i. 5 50) with wild-type or E3-deletion mutant of Ad4
in the absence (2) or in the presence (1) of Ara-C. Ara-C inhibits viral
used. (a) Labeling at 24 and 30 h p.i. in the absence or in the presence
. p.i. indicates hours postinfection. Ad4 and DE3 indicate wild-type and
of the infected cells. (c) Labeled lysates at 27 h p.i. in the absence or9 cells
ionine
in was
9 cellsdisplayed a similar pattern in PAGE and expression level










131CHARACTERIZATION OF Ad4E3-30Kcells in the presence of tunicamycin had a slightly faster
mobility on sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS–PAGE) than the 30K protein syn-
thesized as a cell-free translation product in the absence
of membranes (Fig. 5, compare lane b with lane f); this
suggests that the Ad4E3-30K protein undergoes cleav-
age in vivo of an N-terminal signal sequence.
The vaccinia expression system provided efficient
expression for initial characterization. However, fac-
tors that complicate use of this system include the
concomitant expression of vaccinia proteins, which
could influence the properties of Ad4E3-30K, and the
high level of protein expression, which could obscure
normal events in processing and distribution. There-
fore, other expression systems were investigated to
confirm the initial findings. The Ad4E3-30K cDNA was
inserted into an expression plasmid vector to con-
struct the plasmid pMT2/30K, which contains the hu-
man Ad2 major late promoter and the SV40 origin of
replication. Expression of the Ad4E3-30K protein at
48 h posttransfection of pMT2/30K was detected in
COS cells by immunoprecipitation (Fig. 6, top) and in
SW-13 cells by Western blot analysis (Fig. 7). Similar to
the results with the vaccinia system, multiple bands of
the Ad4E3-30K protein were seen, and these were
restricted to a single 30K band when cells were
treated with tunicamycin. We conclude that the pMT2/
30K and the vaccinia virus-T7 expression systems are
FIG. 5. Endoglycosidase digestion of the Ad4E3-30K protein. The
rotein was expressed in the vaccinia transient expression system in
W-13 cells in the presence or in the absence of tunicamycin. Cell
ysates were subjected to immunoprecipitation using the antiserum to
d4E3-30K, and the recovered proteins were digested with either
NGase F or Endo H. (Lanes a) Vaccinia virus vTF7-3 alone. (b) vTF7-3
lus pcDNA3.1(2)/30K-myc-His plus tunicamycin. (c) Same as (b) but
o tunicamycin. (d) Same as (c) but with PNGase F. (e) Same as (c) but
ith Endo H. (f) “Cell-free” indicates that the 30K protein was synthe-
ized by cell-free translation.useful for characterization of Ad4E3-30K.Glycosylation analysis of the Ad4E3-30K protein
There are six potential N-linked glycosylation sites
(Asn-X-Ser/Thr) located in the predicted lumenal domain
of the Ad4E3-30K protein (Fig. 2, top). The immunopre-
cipitation and Western blot data, which showed that the
multiple bands of Ad4E3-30K were restricted to a single
sharp 30K band in the presence of tunicamycin, suggest
that the protein undergoes multiple N-linked glycosyla-
tion events. To characterize further the N-linked oligo-
saccharides, digestion with N-glycosidases was per-
formed. The protein was labeled with [35S]Met/Cys in
vaccinia-infected SW-13 cells in the absence or in the
presence of tunicamycin. The protein was immunopre-
FIG. 6. Transient expression of the Ad4E3-30K protein in COS cells.
COS cells were transfected with the 30K-expressing plasmid pMT2/30K
and labeled with [35S]cysteine and [35S]methionine in the absence (2)
or in the presence (1) of tunicamycin (lanes c and d). At the top, the
Ad4E3-30K protein was immunoprecipitated from lysates with the rab-
bit antiserum. Proteins were recovered and digested with either PN-
Gase F (lane d) or Endo H (lane c) and analyzed by SDS–PAGE.
“Cell-free” indicates that the 30K protein was synthesized by cell-free
translation (lane a). At the bottom, the Ad4E3-30K protein was immu-
noprecipitated from lysates with the rabbit antiserum (lanes a and b) or
the antiserum preadsorbed with the His6–30K protein (lanes c and d).









132 LI AND WOLDcipitated, incubated with peptide N-glycosidase F (PN-
Gase F) or endoglycosidase H (Endo H), and analyzed by
SDS–PAGE. Tunicamycin treatment, PNGase F digestion,
or Endo H digestion increased the mobility of Ad4E3-30K,
primarily to a major band of 30K (Fig. 5, lanes b, d, and e).
This experiment was also conducted with the pMT2/
30K plasmid transfected into COS-7 cells. Tunicamycin
treatment reduced the multiple 30 to 43K bands of the
Ad4E3-30K protein to a single band of 30K (Fig. 6, top,
compare lanes c and g; Fig. 7). These multiple bands
were also reduced to a single 30K band after digestion
with PNGase F or Endo H (Fig. 6, top, lanes d and e).
Several larger bands ranging from about 60K to .100K
are apparent in lanes c–f of Fig. 6 (top). These bands
were not observed when protein extracts were boiled
prior to incubation with antiserum (data not shown). They
were not observed in Western blots of pMT2/30K-trans-
fected COS-7 cells (Fig. 7). They may represent aggre-
gated forms of Ad4E3-30K or possibly cellular proteins
that coimmunoprecipitated with Ad4E3-30K. To further
address the specificity of these bands, an immunopre-
cipitation experiment was performed using the purified
His6–30K protein to block the antiserum. COS cells were
ransfected with the pMT2/30K plasmid, and the proteins
ere labeled with [35S]Met/Cys in the absence and in the
resence of tunicamycin. Proteins were extracted and
d4E3-30K was immunoprecipitated in the absence or in
he presence of the His6–30K protein. In the absence of
he His6-30K protein, the glycosylated and nonglycosy-
ated forms of Ad4E3-30K were observed (Fig. 6, bottom,
anes a and b). As expected, the His6–30K proteins
blocked the immunoprecipitation of these Ad4E3-30K
proteins (lanes c and d). Only two additional bands were
FIG. 7. Detection of the Ad4E3-30K protein in COS cells by Western
blot. The protein was expressed by transient transfection of the cells
with pMT2/30K in the presence or absence of tunicamycin. Proteins
were separated by SDS–PAGE and detected with polyclonal antisera to
Ad4E3-30K. Results of two separate experiments are shown.obtained in the experiment, one at about 45–50K and the
other near the top of the gel. These bands were notblocked by the His6–30K proteins, so they probably are
background bands.
These experiments demonstrate that Ad4E3-30K un-
dergoes N-glycosylation, and they indicate that the oli-
gosaccharides are of the high-mannose or hybrid type.
They are not of the complex type because they were
digestable by Endo H (Kornfeld and Kornfeld, 1985).
Immunofluorescence staining of the Ad4E3-30K
protein
Detection of the intracellular location of Ad4E3-30K in
Ad4-infected cells by immunofluorescence was unsuc-
cessful due to the appearance of cytopathic effect (CPE)
(rounding up of the cells) by 15 h p.i., which could not be
prevented by addition of Ara-C. This observation sug-
gests that the CPE occurring with Ad4 is mediated by an
early protein(s), in contrast to that in subgroup C, where
it is mediated by late proteins. As an alternative, the
intracellular location of Ad4E3-30K was determined by
immunofluorescence during transient expression. The
rabbit antibody and the secondary antibody did not react
with cellular proteins (Fig. 8a). In the vaccinia system,
staining was observed in SW-13 cells transfected with
the Ad4E3-30K-containing plasmid pcDNA3.1(2)/30K-
myc-His (Figs. 8b and 8c). The predominant staining
pattern appeared to be ER and nuclear membrane. When
the pMT2/30K plasmid was transfected with COS-7 cells,
the predominant staining pattern was also the ER and
nuclear membrane (Fig. 8d). Roughly 10% of the cells had
strong staining of the nuclear membrane and Golgi (Fig.
8e), and about 10% of the cells displayed “blotches” and
“circles” that may be the result of overexpression and
aggregation of the Ad4E3-30K protein (Fig. 8f). Similar
results were obtained with the pMT2/30K plasmid in
SW-13 and MCF-7 cells (data not shown). Importantly,
staining of the plasma membrane was not observed.
These results suggest that the Ad4E3-30K protein local-
izes primarily to the ER including the nuclear membrane
(presumably the outer nuclear membrane). This result is
consistent with our observation that the protein lacks
complex N-linked glycans (Figs. 5 and 6).
DISCUSSION
We postulated that a unique 30K protein would be
encoded in the E3 transcription unit of Ad4, based upon
the presence of an ORF in this region. Antisera raised
against bacterial fusion proteins containing this putative
protein specifically immunoprecipitated a protein of the
predicted size from cell-free translation reactions. This
protein was expressed in Ad4-infected A549 cells, as
indicated by immunoprecipitation with the 30K anti-
serum. This protein could not be obtained from cells
infected with an E3 deletion mutant of Ad4 or from
mock-infected cells. The protein was detected in cells
maintained in Ara-C, indicating that it is expressed dur-
133CHARACTERIZATION OF Ad4E3-30King early stages of infection. However, the protein was
seen in greater abundance at 24–30 h p.i., in the absence
of Ara-C, suggesting that its expression is amplified at
late stages of infection. These results provide strong
evidence that the protein is in fact generated from the E3
region of Ad4 during viral replication. We propose that
the protein be named Ad4E3-30K; it should be given a
more meaningful name once its function is discovered.
Ad4E3-30K was readily detected by immunoprecipita-
tion, immunoblot, or immunofluorescence in cells tran-
siently transfected with plasmids designed to express
the protein. However, detection of the protein in Ad4-
infected cells was possible only in the presence of tuni-
camycin, and the signal was relatively weak compared to
that of the Ad4E3-14.7K (Horton et al., 1990) and E3-
gp19K proteins (unpublished results). Significantly, de-
FIG. 8. Immunofluorescence staining of Ad4E3-30K protein expres-
sion. Cells were transiently transfected with 30K-expressing plasmids.
The Ad4E3-30K protein was detected by immunostaining with anti-
serum against the protein and a goat anti-rabbit FITC conjugate. Im-
ages were taken at 6003 (c) and 10003 (a, b, d–f) magnification. (a)
pMT2 vector (no 30K), COS cells, 48 h posttransfection (calcium phos-
phate). (b, c) pcDNA3.1/30K, SW-13 cells, 6 h posttransfection (vaccinia
virus system). (d–f) pMT2/30K, COS cells, 48 h posttransfection (calci-
um phosphate).tection of the 30K protein was enhanced when an initial
immunoprecipitation step was conducted prior to theWestern blot (data not shown). Most likely, the protein is
synthesized in small amounts in Ad4-infected cells as a
heterogeneous population of molecules in differing
states of glycosylation. Tunicamycin, by preventing gly-
cosylation, would cause the protein to be expressed as
a single species, which would be more easily detected
by the antiserum. It is also possible that heavy glycosyl-
ation of the protein in Ad4-infected cells might hinder the
interaction between the protein and the antiserum. It is
also possible that the protein turns over rapidly in Ad4-
infected cells.
As judged by its predicted sequence, Ad4E3-30K is a
membrane-associated protein containing an NH2-termi-
nal signal peptide sequence, six potential N-linked gly-
cosylation sites in the lumenal domain, an unusually high
content of serine and threonine residues in the lumenal
domain, and a hydrophobic C-terminal transmembrane
region (Fig. 2). Experiments in transfected cells indicated
that Ad4E3-30K acquires multiple N-linked oligosaccha-
rides during posttranslational processing. About six dis-
crete forms of the protein larger than 30K in molecular
weight could be observed (Fig. 6, top, lane c), suggesting
that most or all of the N-linked sites are glycosylated.
Glycosylation was confirmed by PNGase F digestion,
which removed all of the residues (Fig. 6, top, lane d).
The N-linked glycans were sensitive to Endo H, indicat-
ing that they were either high-mannose or hybrid forms,
but not complex types. The functional role of the multiple
carbohydrate residues is unknown. Conceivably, these
glycans could stabilize the protein against proteolytic
degradation, be required for appropriate intracellular
trafficking, or mediate interactions with other proteins.
The deglycosylation analysis suggests that Ad4E3-30K
does not enter the medial/trans-Golgi where it would
acquire complex N-linked glycans. Failure to detect the
protein on the cell surface by immunofluorescence is
consistent with this conclusion.
In immunofluorescence experiments using two differ-
ent transient expression systems, staining of Ad4E3-30K
was seen predominantly in the ER and nuclear mem-
brane. Staining of the plasma membrane was not ob-
served. In about 10% of cells, the Golgi apparatus was
stained. The most straightforward interpretation of these
data is that the protein localizes primarily to the ER.
Staining of the outer nuclear membrane would be ex-
pected because the outer nuclear membrane is contin-
uous with the ER. Staining of the Golgi could occur if the
protein moves from the ER to the intermediate compart-
ment and perhaps the cis-Golgi and then recycles back
to the ER. An ER localization for the protein is consistent
with the lack of complex N-linked glycans on the protein.
A caveat associated with this interpretation is that the
protein is no doubt initially synthesized in the ER, so ER
staining would be observed regardless of the ultimate
destination of the protein. It is important to note that



























































134 LI AND WOLDtems; the localization of Ad4E3-30K in Ad4-infected cells
could be different if, e.g., the protein interacts with an
Ad4-coded protein localized in a different part of the cell.
It is interesting that the E3 transcription unit varies
considerably among the subgroups of human Ads, in
particular in the one to three unique ORFs located be-
tween the gp19K and the RIDa genes (Fig. 1). The E3
proteins encoded by these unique ORFs probably have
functions involved in the modulation of virus replication
or pathogenesis in vivo, based upon the observations
that several conserved E3 proteins counteract host im-
mune defenses and that deletion of the entire E3 region
does not significantly affect the efficiency of viral repli-
cation in culture (Wold et al., 1995c). In subgroup C, the
gene located between gp19K and RIDa encodes ADP, a
rotein with a role in promoting lysis of the host cell and
elease of the virus (Tollefson et al., 1996a,b). In sub-
roup B, a gene encoding a 20.5K membrane glycopro-
ein has been identified and characterized, but its func-
ion is unknown (Hawkins and Wold, 1995a,b; Hawkins et
l., 1995). Also in subgroup B, a gene for a 16K protein is
ocated in the same position in region E3 as the gene for
he 6.7K protein of subgroup C; the 16K protein shares
ome common features with the 6.7K protein; e.g., both
re membrane proteins with patchy homology in the
-terminal cytoplasmic domain (Hawkins et al., 1995).
Of potential interest, Ad4E3-30K and ADP have some
imilar aspects. As mentioned, the genes for both pro-
eins are located in the E3 region between the genes for
p19K and RIDa. Neither Ad4E3-30K nor ADP is required
for efficient virus replication in cultured cells. Indeed, as
is the case with subgroup C, deletion of the entire Ad4 E3
region does not seem to have a major effect on the
replication of Ad4 in cultured cells (Chengalvala et al.,
1997). Both Ad4E3-30K and ADP are membrane glyco-
proteins. However, Ad4E3-30K and ADP also have differ-
ent aspects. In contrast to Ad4E3-30K, ADP has complex
N-linked glycans and localizes primarily to the nuclear
membrane and Golgi (Scaria et al., 1992). There is no
vidence that mutants lacking the Ad4E3-30K or ADP
ave a similar phenotype. Subgroup C mutants that lack
DP have reduced plaque size, consistent with the role
hat ADP plays in mediating the exit of virus from infected
ells (Tollefson et al., 1996b). The Ad4 DE3 mutant, which
acks Ad4E3-30K, does not have small plaques as com-
ared to Ad4. Further studies, such as analysis of Ad4E3-
0K-defective Ad4 viruses, must be undertaken to gain




The A549 cell line (obtained from ATCC) was derived
rom a human lung adenocarcinoma and is permissive
or human Ad infection. SW-13 cells (human adrenocor-ical carcinoma cells) were obtained from ATCC and
rown in minimal essential medium (MEM) plus 10% fetal
ovine serum (FBS). Monkey COS-7 cells and human
CF7 cells were originally obtained from ATCC. Ad
tocks were grown in suspension cultures of human KB
ells (obtained from ATCC), purified by equilibrium den-
ity centrifugation in CsCl, and titered on monolayers of
549 cells (Tollefson et al., 1999). Recombinant vaccinia
virus (vTF7-3) (Fuerst et al., 1986) expressing T7 RNA
polymerase was grown and titered on BHK-21 cells. The
wild-type Ad4 virus was obtained from ATCC. An E3
deletion mutant of Ad4 (Ad4 DE3) and plasmid pAd471–100
containing the Ad4 E3 and E4 regions were obtained
from Dr. Katherine Molnar-Kimber.
Plasmids for cell culture expression
Three different plasmid vectors with the T7 promoter
(pTM1, obtained from Dr. Mark Buller; pcDNA3.1(2)/myc-
His and pCRII, from Invitrogen) and one plasmid vector with
the Ad2 major late promoter (pMT2) (Kaufman et al., 1989)
ere used to construct Ad4E3-30K-expressing plasmids.
he entire Ad4E3-30K nucleotide sequence from the Ad4
3 region containing plasmid pAd471–100 was amplified by
high-fidelity PCR (Stratagene), cloned in-frame into the ex-
pression vectors with the T7 promoter, and confirmed by
DNA sequencing. These three 30K-expressing plasmids
are named pTM1/30K, pcDNA3.1(2)/30K-myc-His, and pC-
II/30K. For construction of the 30K-expressing plasmid
MT2, the Ad4E3-30K insert was exchanged from the
cDNA3.1(2)/30K-myc-His plasmid into the pMT2 plasmid
pMT2/30K).
eneration of antisera against the Ad4E3-30K protein
Construction of Ad4E3-30K expression plasmids for
acterial culture expression. The Ad4E3-30K DNA minus
he portion coding for the N-terminal signal sequence
as amplified by high-fidelity PCR (Stratagene) and
loned using BamHI restriction sites in-frame into two
rokaryotic expression vectors, pGEX-2TK (Pharmacia),
hich encodes the GST protein, and pRSET A (Invitro-
en), which encodes the His6 peptide. The correct ori-
ntation, the reading frame of the constructs, and the
ntegrity of the Ad4E3-30K DNA sequence were con-
irmed by DNA sequence analysis.
Generation of Ad4E3-30K–fusion proteins. GST–30K
nd His6–30K fusion proteins were produced in a pro-
ease-deficient E. coli strain (BL21) and purified from
acterial lysates by affinity chromatography using gluta-
hione–Sepharose 4B for GST–30K (Pharmacia) or immo-
ilized metal affinity chromatography for His6–30K (In-
Vitrogen).
Immunization. Four 2.5- to 3.0-kg female New Zealand
White rabbits were initially immunized subcutaneously at
multiple sites in the back with the GST–30K fusion pro-














































































135CHARACTERIZATION OF Ad4E3-30Kwere similarly inoculated after 21 days with 200 mg of the
His6–30K fusion protein in incomplete Freund’s adjuvant
IFA) and subsequently boosted at biweekly intervals
ith the His6–30K fusion protein (200 mg) in IFA. The
eason for boosting with the His6–30K fusion protein
nstead of GST–30K fusion protein was to prevent further
evelopment of antibodies against GST.
ell-free translation and immunoprecipitation
The Ad4E3-30K protein was synthesized and labeled
n vitro using the plasmid pCRII/30K under control of the
7 promoter in reticulocyte lysates (TNT Coupled Reticu-
ocyte Lysate Systems, Promega) and 0.3 mCi/ml
35S]cysteine (1200 Ci/mmol, DuPont/NEN Research
roducts, Boston, MA). The Ad4E3-30K protein was im-
unoprecipitated using different samples of antisera
rom four rabbits against His6–30K fusion proteins, and
he recovered protein was analyzed by electrophoresis
n 12% SDS–PAGE. 14C-labeled MW markers (Gibco BRL)
were used.
Adenovirus infection and Ad4E3-30K protein
immunoprecipitation
A549 cells (3 3 106 cells per 100-mm dish) were
nfected with Ad4 or Ad4 DE3 at 50 plaque-forming units
PFU) per cell in 1 ml serum-free MEM. At the end of 1 h,
he volume was increased to 10 ml in MEM containing
0% FBS. In some experiments, the MEM contained 20
mg/ml of Ara-C (Sigma). One hour prior to isotope label-
ing, the cells were washed once with Met- and Cys-free
MEM and incubated in MEM in the absence or in the
presence of tunicamycin (10 mg/ml). Cells were labeled
with 100 mCi/ml of [35S]methionine and 100 mCi/ml of
35S]cysteine in 1 ml Met- and Cys-free MEM plus or
inus tunicamycin starting at 4 h before harvest. FBS
as added to 2% at 1 h postlabeling. Proteins were
xtracted in triple-detergent buffer (150 mM NaCl, 0.02%
odium azide, 100 mg/ml PMSF, 1 mg/ml aprotinin, 1%
onidet-P40 (NP-40), 0.5% sodium deoxycholate, 50 mM
ris–HCl, pH 8.0) (Sambrook et al., 1989) containing 0.3%
DS. The Ad4E3-30K protein was immunoprecipitated
nd the sample was electrophoresed in 12% SDS–PAGE
els. 14C-labeled MW markers were used.
accinia virus infection and transient transfection
SW-13 cells were plated on 6-well plates and used
hen almost confluent. Cells were washed once with
erum-free MEM and infected with recombinant vaccinia
irus vTF7-3 at 5 PFU/cell in 300 ml of MEM with 3% calf
erum. At 30 min p.i., cells were washed twice with
erum-free MEM, and 1 mg of plasmid DNA premixed
ith 15 mg of Lipofectin (Gibco BRL) in serum-free MEM
as added. At 2.5 h after transfection, the cells were
ashed and fresh MEM with 5% FBS was added. The
ells were harvested at different time points.alcium phosphate-mediated transient expression
At least 1 mg of plasmid DNA was added to 250 ml of
50 mM CaCl2 and then 250 ml of 23 BES-buffered
aline (23 BBS contains 50 mM BES, pH 6.95, 280 mM
aCl, 1.5 mM Na2HPO4) was added dropwise (Graham
nd Van der Eb, 1973; Chen and Okayama, 1987). Five
undred microliters of the mixture was added to the cells
n a 60-mm dish overnight. The medium was changed the
ext day. The cells were harvested at different time
oints.
mmunoblot and immunoprecipitation from
ransfected cells
The procedure for vaccinia virus infection and tran-
ient transfection (stated above) was used. For immuno-
lotting, the cells were washed and proteins were ex-
racted at 8 h after transfection, resolved on 12% SDS
els, electroblotted onto a PVDF membrane (Millipore),
nd reacted with a 1:250 dilution of the Ad4E3-30K anti-
erum. Horseradish peroxidase (HRP)-conjugated goat
nti-rabbit immunoglobulin G and HRP Color Develop-
ent Reagent (Bio-Rad) were used. Prestained molecu-
ar weight markers were obtained from Bio-Rad. For
mmunoprecipitation, the cells were labeled with 100
mCi/ml of [35S]methionine and 100 mCi/ml of [35S]cysteine
n the presence or in the absence of tunicamycin. The
xtraction and immunoprecipitation procedures were
one as described above.
igestion with endoglycosidase
Immunoprecipitations were performed as described
bove. For Endo H digestion, the samples collected on
eads were washed once with 0.1 M sodium citrate (pH
.5), resuspended in 10 ml of boiling buffer (1 ml of 10%
DS, 9 ml of 10 mM Tris–HCl, pH 6.8–7.0), boiled at 100°C
or 3 min, and centrifuged. The supernatant was trans-
erred to a fresh microfuge tube and treated with 2 units
f Endo H (Boehringer Mannheim) in 20 ml of 0.1 M
odium citrate (pH 5.5) with 25 mM phenylmethylsulfonyl
luoride, and then incubated at 37°C for 16 h. For PN-
ase F digestion, the samples were collected on aga-
ose beads, washed with PNGase F buffer (0.02 M so-
ium phosphate, pH 6.1, 50 mM EDTA, 0.5% NP-40 (v/v),
0 mM NaN3), resuspended in 10 ml of 1% SDS solution,
and boiled for 2 min. This was followed by addition of 90
ml of PNGase F buffer and boiling for an additional 2 min.
The supernatant was transferred to a fresh microfuge
tube, treated with 5 U of PNGase F, and then incubated
at 37°C for 15 to 20 h. For analysis of reaction products,
Laemmli gel sample buffer was added to terminate the
reactions, and then the samples were heated and sub-
jected to SDS–PAGE.
B136 LI AND WOLDImmunofluorescence staining of transfected cells
SW-13 cells or COS cells were plated onto glass cov-
erslips. The 30K-expressing plasmids with the T7 pro-
moter were transfected into cells using Lipofectin follow-
ing infection of cells with recombinant vaccinia virus
vTF7-3 at a multiplicity of 5 PFU/cell. Alternatively, the
30K-expressing plasmid pMT2/30K was transfected into
cells using calcium phosphate, independent of vaccinia
virus infection, as described above. The cells were fixed
in paraformaldehyde for 10 min at room temperature,
permeabilized using methanol containing DAPI stain (at
220°C) for 6 min, and finally treated with methanol alone
for 2 min. Coverslips were washed three times with PBS,
incubated with a 1:100 dilution of the preabsorbed rabbit
anti-30K antibody for 60 min, rinsed with PBS, and sub-
sequently incubated with a 1:50 dilution of fluorescein
isothiocyanate (FITC)-conjugated goat anti-rabbit IgG
(Organon Teknika, Durham, NC) (Scaria et al., 1992) for
30 min.
ACKNOWLEDGMENTS
This research was supported by Grant CA24710 from the National
Institutes of Health. The Ad4 mutant virus (Ad4DE3) was kindly sup-
plied by Katherine Molnar-Kimber.
REFERENCES
Anderson, M., Paabo, S., Nilsson, T., and Peterson, P. A. (1985). Im-
paired intracellular transport of class I MHC antigens as a possible
means for adenoviruses to evade immune surveillance. Cell 43,
215–222.
Anderson, M., McMichael, A., and Peterson, P. A. (1987). Reduced
allorecognition of adenovirus-2 infected cells. J. Immunol. 138, 3960–
3966.
Babaloa, O. E., Amoni, S. S., Samaila, E., Thaker, U., and Darougar, S.
(1990). An outbreak of acute haemorrhagic conjunctivitis in Kaduna,
Nigeria. Br. J. Ophthalmol. 74, 89–92.
arraza, E. M., Ludwig, S. L., Gaydos, J. C., and Brundage, J. F. (1999).
Reemergence of adenovirus type 4 acute respiratory disease in
military trainees: Report of an outbreak during a lapse in vaccination.
J. Infect. Dis. 179, 1531–1533.
Burgert, H. G., and Kvist, S. (1985). An adenovirus type 2 glycoprotein
blocks cell surface expression of human histocompatibility class I
antigens. Cell 41, 987–997.
Burgert, H. G., Maryanski, J. L., and Kvist, S. (1987). “E3/19K” protein of
adenovirus type 2 inhibits lysis of cytolytic T lymphocytes by blocking
cell-surface expression of histocompatibility class I antigens. Proc.
Natl. Acad. Sci. USA 84, 1356–1360.
Carlin, C. R., Tollefson, A. E., Brady, H. A., Hoffman, B. L., and Wold,
W. S. M. (1989). Epidermal growth factor receptor is down-regulated
by a 10,400 MW protein encoded by the E3 region of adenovirus. Cell
57, 135–144.
Chen, C., and Okayama, H. (1987). High-efficiency transformation of
mammalian cells by plasmid DNA. Mol. Cell. Biol. 7, 2745–2752.
Chengalvala, M. V., Lubeck, M. D., Selling, B. J., Natuk, R. J., Hsu, K. H.,
Mason, B. B., Chanda, K. K., Bhat, R. A., Bhat, B. M., and Mizutani, S.
(1991a). Adenovirus vectors for gene expression. Curr. Opin. Biotech-
nol. 2, 718–722.Chengalvala, M., Lubeck, M. D., Davis, A. R., Mizutani, S., Molnar-
Kimber, K., Morin, J., and Hung, P. P. (1991b). Evaluation of adenovirustype 4 and type 7 recombinant hepatitis B vaccines in dogs. Vaccine
9, 485–490.
Chengalvala, M. V., Bhat, B. M., Bhat, R., Lubeck, M. D., Mizutani, S.,
Davis, A. R., and Hung, P. P. (1994). Immunogenicity of high expres-
sion adenovirus-hepatitis B virus recombinant vaccines in dogs.
J. Gen. Virol. 75, 125–131.
Chengalvala, M. V., Bhat, B. M., Bhat, R. A., Dheer, S. K., and Lubeck,
M. D. (1997). Replication and immunogenicity of Ad7–, Ad4–, and
Ad5–hepatitis B virus surface antigen recombinants, with or without
a portion of E3 region, in chimpanzees. Vaccine 15, 335–339.
Dudding, B. A., Top, F. H., Jr., Scott, R. M., Russell, P. K., and Buescher,
E. L. (1972). An analysis of hospitalizations for acute respiratory
disease in recruits immunized with adenovirus type 4 and type 7
vaccines. Am. J. Epidemiol. 95, 140–147.
Elsing, A., and Burgert, H. G. (1998). The adenovirus E3/10.4K-14.5K
proteins down-modulate the apoptosis receptor Fas/Apo-1 by induc-
ing its internalization. Proc. Natl. Acad. Sci. USA 95, 10072–10077.
Fuerst, T. R., Niles, E. G., and Studier, F. W. (1986). Eukaryotic transient-
expression system based on recombinant vaccinia virus that synthe-
sizes bacteriophage T7 RNA polymerase. Proc. Natl. Acad. Sci. USA
83, 8122–8126.
Gooding, L. R., Elmore, L. W., Tollefson, A. E., Brady, H. A., and Wold,
W. S. M. (1988). A 14,700 MW protein from the E3 region of adeno-
virus inhibits cytolysis by tumor necrosis factor. Cell 53, 341–346.
Gooding, L. R., Sofola, I. O., Tollefson, A. E., Duerksen-Hughes, P., and
Wold, W. S. M. (1990). The adenovirus E3–14.7K protein is a general
inhibitor of tumor necrosis factor-mediated cytolysis. J. Immunol. 145,
3080–3086.
Gooding, L. R., Ranheim, T. S., Tollefson, A. E., Aquino, L., Duerksen-
Hughes, P., Horton, T. M., and Wold, W. S. M. (1991). The 10,400- and
14,500-Dalton proteins encoded by region E3 of adenovirus function
together to protect many but not all mouse cell lines against lysis by
tumor necrosis factor. J. Virol. 65, 4114–4123.
Graham, F. L., and Van der Eb, A. J. (1973). A new technique for the
assay of infectivity of human adenovirus 5 DNA. Virology 52, 456–
467.
Gruber, W. C., Russell, D. J., and Tibbetts, C. (1993). Fiber gene and
genomic origin of human adenovirus type 4. Virology 196, 603–611.
Hawkins, L. K., and Wold, W. S. M. (1992). A 12,500 MW protein is coded
by region E3 of adenovirus. Virology 188, 486–494.
Hawkins, L. K., and Wold, W. S. M. (1995a). A 20,500-dalton protein is
coded by region E3 of subgroup B but not subgroup C human
adenoviruses. Virology 208, 226–233.
Hawkins, L. K., and Wold, W. S. M. (1995b). The E3–20.5K membrane
protein of subgroup B human adenoviruses contains O-linked and
complex N-linked oligosaccharides. Virology 210, 335–344.
Hawkins, L. K., Wilson-Rawls, J., and Wold, W. S. M. (1995). Region E3
of subgroup B human adenoviruses encodes a 16-kilodalton mem-
brane protein that may be a distant analog of the E3–6.7K protein of
subgroup C adenoviruses. J. Virol. 65, 4292–4298.
Horton, T. M., Tollefson, A. E., Wold, W. S. M., and Gooding, L. R. (1990).
A Protein serologically and functionally related to the group C E3
14,700-kilodalton protein is found in multiple adenovirus serotypes.
J. Virol. 64, 1250–1255.
Horton, T. M., Ranheim, T. S., Aquino, L., Kusher, D. I., Saha, S. K., and
Ware, C. F. (1991). Adenovirus E3–14.7K protein functions in the
absence of other adenovirus proteins to protect transfected cells
from tumor necrosis factor cytolysis. J. Virol. 65, 2629–2639.
Horwitz, M. S. (1996). Adenovirus. In “Fields Virology” (B. N. Fields, D. M.
Knipe, and P. M. Howley, Eds.), 3rd ed., pp. 2149–2171. Lippincott–
Raven, Philadelphia.
Hsu, K. H., Lubeck, M. D., Davis, A. R., Bhat, R. A., Selling, B. H., Bhat,
B. M., Mizutani, S., Murphy, B. R., Collins, P. L., and Chanock, R. M.
(1992). Immunogenicity of recombinant adenovirus-respiratory syn-
cytial virus vaccines with adenovirus types 4, 5, and 7 vectors in dogs
and a chimpanzee. J. Infect. Dis. 166, 769–775.












137CHARACTERIZATION OF Ad4E3-30KB. H., Mizutani, S., Davis, A. R., and Hung, P. P. (1994). Efficacy of
adenovirus-vectored respiratory syncytial virus vaccines in a new
ferret model. Vaccine 12, 607–612.
ackson, M. R., Nilsson, T., and Peterson, P. A. (1993). Retrieval of
transmembrane proteins to the endoplasmic reticulum. J. Cell. Biol.
121, 317–333.
aufman, R. J., Davies, M. V., Pathak, V. K., and Hershey, J. W. B. (1989).
The phosphorylation state of eukaryotic initiation factor 2 alters
translational efficiency of specific mRNAs. Mol. Cell. Biol. 9, 946–958.
ornfeld, R., and Kornfeld, S. (1985). Assembly of asparagine-linked
oligosaccharides. Annu. Rev. Biochem. 54, 631–664.
rajcsi, P., Dimitrov, T., Hermiston, T. W., Tollefson, A. E., Ranheim, T. S.,
Vande Pol, S. B., Stephenson, A. H., and Wold, W. S. M. (1996). The
adenovirus E3–14.7K protein and the E3–10.4K/14.5K complex of
proteins, which independently inhibit tumor necrosis factor (TNF)-
induced apoptosis, also independently inhibit TNF-induced release
of arachidonic acid. J. Virol. 70, 4904–4913.
vist, S., Ostberg, L., Persson, H., Philipson, L., and Peterson, P. A.
(1978). Molecular association between transplantation antigens and
cell surface antigen in adenovirus-transformed cell line. Proc. Natl.
Acad. Sci. USA 75, 5674–5678.
evandowski, R. A., and Rubenis, M. (1981). Nosocomial conjunctivitis
caused by adenovirus type 4. J. Infect. Dis. 143, 28–31.
evin, S., Dietrich, J., and Guillory, J. (1967). Fatal nonbacterial pneumo-
nia associated with adenovirus type 4 occurrence in an adult. J. Am.
Med. Assoc. 201, 975–977.
i, Y., Kang, J., and Horwitz, M. (1997). Interaction of an adenovirus
14.7-kilodalton protein inhibitor of tumor necrosis factor alpha cytol-
ysis with a new member of the GTPase superfamily of signal trans-
ducers. J. Virol. 71, 1576–1582.
i, Y., Kang, J., and Horwitz, M. (1998). Interaction of an adenovirus E3
14.7-kilodalton protein with a novel tumor necrosis factor alpha-
inducible cellular protein containing leucine zipper domains. Mol.
Cell. Biol. 18, 1601–1610.
i, Y., Kang, J., Friedman, J., Tarassishin, L., Ye, J., Kovalenko, A., Wallach,
D., and Horwitz, M. (1999). Identification of a cell protein (FIP-3) as a
modulator of NF-kB activity and as a target of an adenovirus inhibitor
of tumor necrosis factor a-induced apoptosis. Proc. Natl. Acad. Sci.
USA 96, 1042–1047.
Lubeck, M. D., Natuk, R. J., Chengalvala, M., Chansa, P. K., Murthy, K. K.,
Murthy, S., Mizutani, S., Lee, S. G., Wade, M. S., and Bhat, B. M. (1995).
Immunogenicity of recombinant adenovirus-human immunodefi-
ciency virus vaccines in chimpanzees following intranasal adminis-
tration. AIDS Res. Hum. Retroviruses 10, 1443–1449.
Mahr, J., and Gooding, L. R. (1999). Immune evasion by adenoviruses.
Immunol. Rev. 168, 121–130.
Muzzi, A., Rocchi, G., Lumbroso, B., Tosato, G., and Barbieri, F. (1975).
Acute haemorrhagic conjunctivitis during an epidemic outbreak of
adenovirus-type-4 infection. Lancet 2, 822–823.
Natuk, R. J., Chanda, P. K., Lubeck, M. D., Davis, A. R., Wilhelm, J., Hjorth,
R., Wade, M. S., Bhat, B. M., Mizutani, S., and Lee, S. (1992). Adeno-
virus-human immunodeficiency virus (HIV) envelope recombinant
vaccines elicit high-titered HIV-neutralizing antibodies in the dog.
Proc. Natl. Acad. Sci. USA 89, 7771–7781.
Natuk, R. J., Davis, A. R., Chanda, P. K., Lubeck, M. D., Chengalvala, M.,
Murthy, S. C., Wade, M. S., Dheer, S. K., Bhat, B. M., and Murthy, K. K.
(1994). Adenovirus vectored vaccines. Dev. Biol. Stand. 82, 71–77.
Natuk, R. J., Wade, M. S., Chengalvala, M., Murthy, K. K., Chansa, P. K.,
Murthy, S. C., Bhat, B. M., Bhat, R., Dheer, S. K., and Mizutani, S.
(1995). Adenovirus as a vector for HIV: Efficacy and safety issues.
Dev. Biol. Stand. 84, 153–156.
Paabo, S., Weber, F., Kampe, O., Schaffner, W., and Peterson, P. A.
(1983). Association between transplantation antigens and a viral
membrane protein synthesized from a mammalian expression vec-
tor. Cell 33, 445–453.Rosenvaum, M. J., De Berry, P., Sullivan, E. J., Edwards, E. A., Pierce,
W. E., Muldoon, R. L., Jackson, G. G., and Peckinpaugh, R. O. (1968).Characteristics of vaccine-induced and natural infection with adeno-
virus type 4 in naval recruits. Am. J. Epidermiol. 88, 45–54.
Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). “Molecular Cloning:
A Laboratory Manual,” 2nd ed. Cold Spring Harbor Laboratory Press,
Cold Spring Harbor, NY.
Scaria, A., Tollefson, A. E., Saha, S., and Wold, W. S. M. (1992). The
E3–11.6K protein of adenovirus is an Asn-glycosylated integral mem-
brane protein that localizes to the nuclear membrane. Virology 191,
743–753.
Schepetiuk, S. K., Norton, R., Kok, T., and Irving, L. G. (1993). Outbreak
of adenovirus type 4 conjunctivitis in South Australia. J. Med. Virol. 41,
316–318.
Shenk, T. (1996). Adenoviridae: The viruses and their replication. In
“Fields Virology” (B. N. Fields, D. M. Knipe, and P. M. Howley, Eds.),
3rd ed., pp. 2111–2148. Lippincott–Raven, Philadelphia.
Shisler, J., Yang, C., Walter, B., Ware, C. F., and Wold, W. S. M. (1997). The
adenovirus E3–10.4K/14.5K complex mediates loss of cell surface
Fas (CD95) and resistance to Fas-induced apoptosis. J. Virol. 71,
8299–8306.
Sonoguchi, T., and Fukumi, H. (1967). Causes of common cold in new
recruits, with reference to the significance of adenovirus type-4.
Nippon Ishikai Zasshi [J. Jpn. Med. Assoc.] 57, 1540–1542. [In Japa-
nese]
Stewart, A. R., Tollefson, A. E., Krajcsi, P., Yei, S., and Wold, W. S. M.
(1995). The adenovirus E3–10.4K and 14.5K proteins, which function
to prevent cytolysis by tumor necrosis factor and to down-regulate
the epidermal growth factor receptor, are localized in the plasma
membrane. J. Virol. 69, 172–181.
Tollefson, A. E., Stewart, A. R., Yei, S., Saha, A. K., and Wold, W. S. M.
(1991). The 10,400- and 14,500-dalton proteins encoded by region E3
of adenovirus form a complex and function together to down-regulate
the epidermal growth factor receptor. J. Virol. 65, 3095–3105.
Tollefson, A. E., Scaria, A., Saha, A. K., and Wold, W. S. M. (1992). The
11,600-Mw protein encoded by region E3 of adenovirus is expressed
early but is greatly amplified at late stage of infection. J. Virol. 66,
3633–3642.
ollefson, A. E., Scaria, A., Hermiston, T. W., Ryerse, J. S., and Wold,
W. S. M. (1996a). The adenovirus death protein (E3–11.6K) is required
at very late stages of infection for efficient cell lysis and release of
adenovirus from infected cells. J. Virol. 70, 2296–2306.
ollefson, A. E., Ryerse, J. S., Scaria, A., Hermiston, T. W., and Wold,
W. S. M. (1996b). The E3–11.6-kDa adenovirus death protein (ADP) is
required for efficient cell death: Characterization of cells infected
with adp mutants. Virology 220, 152–162.
Tollefson, A., Hermiston, T. W., Lichtenstein, D. L., Colle, C. F., Tripp,
R. A., Dimitrov, T., Toth, K., Wells, C. E., Doherty, P. C., and Wold,
W. S. M. (1998). Forced degradation of Fas inhibits apoptosis in
adenovirus-infected cells. Nature 392, 727–730.
Tollefson, A., Hermiston, T. W., and Wold, W. S. M. (1999). Preparation
and titration of CsCl-banded adenovirus stock. In “Adenovirus Meth-
ods and Protocols” (W. S. M. Wold, Ed.), pp. 1–10. Humana Press,
Clifton, NJ.
Top, F. H., Jr. (1975). Control of adenovirus acute respiratory disease in
U.S. Army trainees. Yale J. Biol. Med. 48, 185–195.
Top, F. H., Jr., Grossman, R. A., Bartelloni, P. J., Segal, H. E., Dudding,
B. A., Russell, P. K., and Buscher, E. L. (1971). Immunization with live
type 7 and 4 adenovirus vaccine in humans. J. Infect. Dis. 124,
148–154.
Tsuki-Wang, L., Aoki, K., Isobe, K., Shiao, S., Toba, K., Kobayashi, N.,
Noguchi, Y., and Ohno, S. (1997). Genome analysis of adenovirus
type 4 strains isolated from acute conjunctivitis in Japan. Jpn. J.
Ophthalmol. 41, 308–311.
Tullo, A. B., and Higgins, P. G. (1980). An outbreak of adenovirus type 4
conjunctivitis. Br. J. Ophthalmol. 64, 489–493.
Voelkel-Johnson, C., Entingh, A. J., Wold, W. S. M., Gooding, L. R., and
Laster, S. M. (1995). Activation of intracellular proteases is an early
event in TNF-induced apoptosis. J. Immunol. 154, 1707–1716.
Z138 LI AND WOLDWilson-Rawls, J., Deutscher, S. L., and Wold, W. S. M. (1994). The
signal-anchor domain of adenovirus E3–6.7K, a type III integral mem-
brane protein, can direct adenovirus E3-gp19K, a type I integral
membrane protein, into the membrane of the endoplasmic reticulum.
Virology 201, 66–76.
Wilson-Rawls, J., Saha, S. K., Krajcsi, P., Tollefson, A. E., Gooding, L. R.,
and Wold, W. S. M. (1990). A 6700 MW membrane protein is encoded
by region E3 of adenovirus type 2. Virology 178, 204–212.
Wilson-Rawls, J., and Wold, W. S. M. (1993). The E3–6.7K protein of
adenovirus is an Asn-linked integral membrane glycoprotein local-
ized in the endoplasmic reticulum. Virology 195, 6–15.
Wold, W. S. M., and Gooding, L. R. (1991). Region E3 of adenovirus: A
cassette of genes involved in host immunosurveillance and virus–
cell interactions. Virology 184, 1–8.
Wold, W. S. M., Hermiston, T. W., and Tollefson, A. E. (1995a). Strategies
of immune modulation by adenoviruses. In “Viroreceptors, Virokines,
and Related Mechanisms of Immune Modulation by DNA Viruses”
(G. McFadden, Ed.), pp. 145–183. R. G. Landes, Austin, TX.
Wold, W. S. M., Hermiston, T. W., and Tollefson, A. E. (1995b). Functions
of the adenovirus E3 proteins. Curr. Top. Microbiol. Immunol. 199,
237–274.Wold, W. S. M., Tollefson, A. E., and Hermiston, T. W. (1995c). E3
transcription unit of adenovirus. In “The Molecular Repertoire of
Adenoviruses” (W. Doerfler and P. Bohm, Eds.), pp. 237–274. Springer-
Verlag, Heidelberg.
Wold, W. S. M., and Tollefson, A. E. (1998). Adenovirus E3 proteins:
14.7K, RID, and gp19K inhibit immune-induced cell death; Adenovirus
death protein promotes cell death. Semin. Virol. 8, 515–523.
Wold, W. S. M., and Tollefson, A. E. (1999). Adenovirus–host interactions
to subvert the host immune system. In “Adenoviruses: Basic Biology
to Gene Therapy” (P. Seth, Ed.), pp. 245–252. R. G. Landes, Austin, TX.
Wold, W. S. M., Toth, K., Doronin, K., Kuppuswamy, M., Lichtenstein,
D. L., and Tollefson, A. E. (1999a). Adenovirus inhibition of immune-
mediated apoptosis. Clin. Immunol. Newslett. 19, 1–7.
Wold, W. S. M., Doronin, K., Toth, K., Kuppuswamy, M., Lichtenstein,
D. L., and Tollefson, A. E. (1999b). Immune responses to adenovi-
ruses: Viral evasion mechanisms and their implications for the clinic.
Curr. Opin. Immunol. 11, 380–386.
illi, D., Voelkel-Johnson, C., Skinner, T., and Laster, S. M. (1992). The
adenovirus E3 region 14.7 kDa protein, heat and sodium arsenite
inhibit the TNF-induced release of arachidonic acid. Biochem. Bio-
phys. Res. Commun. 188, 177–183.
